IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: H. Michael SHEPARD et al.

Title: ENZYME CATAZYZED

THERAPEUTIC AGENTS

Appl. No.: 09/782,721

Filing Date: 2/12/2001

Examiner: Crane, Lawrence E.

Art Unit: 1623

Confirmation 5394

Number:

CERTIFICATE OF ELECTRONIC TRANSMISSION
I bereby corrigh that his paper is being electronically transmitted to the
United States Patent and Trademark Office, Alexandria, Virginia via
EFS-Web on the date below

Laura Davis

(Printed Name)

September 5, 2007 (Date of Transmission)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of a document known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR \$1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR \$1.97 and \$1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to

SVCA 72059.1

antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed document is being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP 8609.

FEE

Fees in the amount of \$180.00 in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c) are being paid by credit card via EFS-Web.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or

SVCA_72059.1

Atty. Dkt. No. 060925-0402

incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Left 5 2007

FOLEY & LARDNER LLP Customer Number: 38706 Telephone: (650) 251-1129

Facsimile: (650) 856-3710

By automate Konski

Antoinette F. Konski Attorney for Applicant Registration No. 34,202

PTO/SB/08 (09-06) Approved for use through 03/31/2007, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

iumoer.								
		Substitute for form	1449/F	PTO		Complete if Known		
	11	NFORMATION DIS	SCLO	SURE	Application Number	09/782,721		
STATEMENT BY APPLICANT					Filing Date	2/12/2001		
Date Submitted: September 5, 2007 (use as many sheets as necessary)					First Named Inventor	H. Michael Shepard		
					Art Unit	1623		
					Examiner Name	Crane, Lawrence E.		
Sheet		1	of	1	Attorney Docket Number	060925-0402		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ (Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6

NON PATENT LITERATURE DOCUMENTS						
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calatog, etc.) date, page(s), volume-issue number(s), publisher, citly and/or country where published.					
	SMITH et al. "Preliminary Correlations of Clinical Outcome with <i>in Vitro</i> Chemosensitivity of Second Passage Human Breast Cancer Cells," Cancer Res. 50 (10):2943-2948 (May 1990)					
		T				
		+-				
		Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. SMITH et al. "Preliminary Correlations of Clinical Outcome with in Vitro Chemosensitivity of Second				

Examiner Signature		Date Considered]		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPED 600. Draw line through citation if not in conformance and not considered.					

Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible, 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to

process) an application. Confidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.14. This document is useful as the place to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for recluding this burden, should be sent to the first information of art Tademark Office. Son 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.